Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,942 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2-, node-positive, high-risk early breast cancer in Italy.
Davie A, Traoré S, Giovannitti M, Pompilio G, Lambton M, Cakar E, Chatterjee A. Davie A, et al. Among authors: chatterjee a. Glob Reg Health Technol Assess. 2023 Sep 28;10:62-69. doi: 10.33393/grhta.2023.2561. eCollection 2023 Jan-Dec. Glob Reg Health Technol Assess. 2023. PMID: 37811343 Free PMC article.
Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.
Chatterjee A, Shapouri S, Manzoor BS, Ravelo A, Sail K, Qendri V, van de Wetering G, Davids MS. Chatterjee A, et al. J Manag Care Spec Pharm. 2021 Nov;27(11):1532-1544. doi: 10.18553/jmcp.2021.27.11.1532. J Manag Care Spec Pharm. 2021. PMID: 34714110 Free PMC article.
BACKGROUND: Chronic lymphocytic leukemia (CLL) is a significant health and economic burden in the United States. ...The model estimated life-years gained, quality-adjusted life-years (QALYs) gained, and costs. The time horizon was 20 years, with a cycle time of 28 d …
BACKGROUND: Chronic lymphocytic leukemia (CLL) is a significant health and economic burden in the United States. ...The model estimat …
Exploring the Limits of Endovascular Therapy for Large Core Patients: Where Do We Need More Data?
Albers GW, Heit JJ, Lansberg MG, Inoue M, Huo X, Yedavalli VS, Seners P, McCullough-Hicks M, Cereda CW, Tsai JP, Mistry EA, Chatterjee AR, Derdeyn CP, Khatri P, Olivot JM, Hill MD, Saver JL, Fisher M. Albers GW, et al. Among authors: chatterjee ar. Stroke. 2024 Jun 5. doi: 10.1161/STROKEAHA.124.047228. Online ahead of print. Stroke. 2024. PMID: 38836345 No abstract available.
Gastroparesis for the nongastroenterologist.
Araujo-Duran J, Chatterjee A, Garg S. Araujo-Duran J, et al. Among authors: chatterjee a. Cleve Clin J Med. 2024 Jun 3;91(6):373-383. doi: 10.3949/ccjm.91a.23078. Cleve Clin J Med. 2024. PMID: 38830702 Free article. Review.
3,942 results